Veerle Vanvoorden
Veerle Vanvoorden publishes mostly in Immunology, Oncology and Rheumatology, on topics such as Psoriasis: Treatment and Pathogenesis, Spondyloarthritis Studies and Treatments and Autoimmune Bullous Skin Diseases.
- World rank
- #1,217,511 of 7,710,434 ranked researchers
- Rank in Belgium
- #11,137 of 67,186
- Works
- 36
- Citations
- 1.9k
- Citations per work
- 53.5
What does Veerle Vanvoorden research?
Veerle Vanvoorden's work is mostly in Medicine (39%), Immunology and Microbiology (29%), Economics, Econometrics and Finance (8%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1439.0%
- Medicine1439.0%
- Life Sciences1028.6%
- Immunology and Microbiology1028.6%
- Everything else924.8%
- Social Sciences37.6%
- 1Immunology29% of their works
- 2Oncology14% of their works
- 3Rheumatology10% of their works
- 4Dermatology8% of their works
- 5Pathology and Forensic Medicine8% of their works
- 6Economics and Econometrics8% of their works
Research topics
- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
- Autoimmune Bullous Skin Diseases
- Dermatology and Skin Diseases
- Cancer survivorship and care
- Health Systems, Economic Evaluations, Quality of Life
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
Which keywords describe Veerle Vanvoorden's research?
The keywords of their largest research topics: IL-17, TH17 Cells, Quality of Life, Ankylosing Spondylitis, Spondyloarthritis, Autoantibodies, Pemphigoid and Filaggrin.
- KRAS Mutations
- Cetuximab
- Health Utility Measures
- Cancer Survivorship
- Filaggrin
- Autoantibodies
- Ankylosing Spondylitis
- TH17 Cells
- IL-17
- Quality of Life
- Spondyloarthritis
- Pemphigoid
- Skin Microbiome
- Cost-effectiveness Analysis
- Patient-Reported Outcomes
- Fc Receptors
- Therapeutic Antibodies
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 17 words, with their numbers
- IL-17261 topic
- TH17 Cells261 topic
- Quality of Life122 topics
- Ankylosing Spondylitis91 topic
- Spondyloarthritis91 topic
- Autoantibodies81 topic
- Pemphigoid81 topic
- Filaggrin71 topic
- Skin Microbiome71 topic
- Cancer Survivorship61 topic
- Cost-effectiveness Analysis61 topic
- Health Utility Measures61 topic
- Patient-Reported Outcomes61 topic
- Cetuximab41 topic
- Fc Receptors41 topic
- KRAS Mutations41 topic
- Therapeutic Antibodies41 topic
Where does Veerle Vanvoorden work?
Veerle Vanvoorden's main affiliation in the publication record is UCB Pharma (Belgium), Belgium.
How many publications and citations does Veerle Vanvoorden have?
OpenAlex counts 36 works and 1,925 citations for Veerle Vanvoorden, an h-index of 14, ranking #1,217,511 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Veerle Vanvoorden. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.